BIO-TECHNE Corp
TECH- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000842023
No open-market purchases or sales by BIO-TECHNE Corp insiders were filed in the last 90 days; 597 institutions reported holding it in 13F filings for Q2 2026, worth $12.3B in total; 3 superinvestors hold it, including Maverick Capital and Weitz Investment Management.
Q3 2022 vs. Q2 2022
How the institutions holding BIO-TECHNE Corp changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 551 | 6 | 536 | −9 |
| Shares | 37.2M | 5.69K | 38.0M | +817.3K (+2.2%) |
| Value | $12.9B | $1.97M | $10.8B | −$2.10B (−16.3%) |
6 institutions that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (47)
Institutions that held BIO-TECHNE Corp at the end of Q3 2022 but not at the end of Q2 2022.
Sold out (56)
Institutions that held BIO-TECHNE Corp at the end of Q2 2022 and filed for Q3 2022 without it.
Not filed for Q3 2022 yet (6)
Institutions that held BIO-TECHNE Corp at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Icon Wealth Partners, LLC | 3,155 | $1.09M |
| Coldstream Capital Management Inc | 1,199 | $416.0K |
| Advisor Partners LLC | 830 | $288.0K |
| Exane Derivatives | 407 | $141.1K |
| Private Capital Group, LLC | 54 | $19.0K |
| Fieldpoint Private Securities, LLC | 45 | $16.0K |